Nebivolol 089pharm

Nebivolol, the active ingredient in Nebivolol 089pharm, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivolol 089pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure in adults. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms in chronic heart failure. Elderly patients with hypertension: provides effective blood pressure control with added vasodilatory benefit.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness during daily activities. - Nasal congestion or rhinorrhea. - Bradycardia: heart rate below normal resting levels. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope. - Marked hypotension causing fainting. - Atrioventricular block or other conduction abnormalities. - Bronchospasm in patients with reactive airway disease. - Allergic reactions including rash, angioedema, or anaphylaxis. - Elevated liver enzymes indicating hepatic stress.

Before initiating Nebivolol, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive drop. Assess cardiac function: evaluate for existing bradyarrhythmias. Review concomitant beta‑blockers: avoid additive effects. Use caution in asthma or COPD: risk of bronchospasm. Adjust dose in renal impairment: consider reduced clearance. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine): increase nebivolol plasma levels. - Calcium‑channel blockers that affect AV node (e.g., verapamil, diltiazem): risk of severe bradycardia. - Clonidine abrupt withdrawal: may precipitate hypertensive crisis. - Antiarrhythmic class IA agents: enhanced conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for additive hypotension. - Other antihypertensives: adjust dose to avoid over‑lowering BP. - Certain antidepressants (e.g., SSRIs): observe for heart rate changes.